Stock PSTX POSEIDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
2.13 USD +3.90% Intraday chart for Poseida Therapeutics, Inc. +5.45% -36.61%
04-08 Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma CI
03-25 Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
AQ
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
PR
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
CI
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer
MT
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024
CI
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PR
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M
MT
Poseida Therapeutics : Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 - Form 8-K
PU
Poseida Therapeutics, Inc. Announces Executive Changes
CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index
CI
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating
MT
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial
MT
Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment
DJ
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating
MT
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting
CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Posts Q3 Revenue $9.4M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSTX Stock
  4. News Poseida Therapeutics, Inc.